The making of a user friendly MAOI diet

Journal of Clinical Psychiatry

Volumn 57, Issue 3, 1996, Pages 99-104

  Gardner, David M ^a   Shulman, Kenneth I ^a,b   Walker, Scott E ^a   Tailor, Sandra A N ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PHENELZINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; TYRAMINE;

ARTICLE; BEER; CHEESE; DEPRESSION; DIET RESTRICTION; FAVISM; FOOD DRUG INTERACTION; FOOD INTAKE; HUMAN; HYPERTENSION; MEAT INDUSTRY; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ACUTE DISEASE; ANIMALS; BEER; CHEESE; DEPRESSIVE DISORDER; DIET; FISHES; FOOD-DRUG INTERACTIONS; FRUIT; HUMANS; HYPERTENSION; MEAT; MONOAMINE OXIDASE INHIBITORS; POULTRY; TYRAMINE; VEGETABLES;

EID: 0029985826     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Blackwell B. Hypertensive crisis due to monoamine-oxidase inhibitors. Lancet 1963;2:849-851
2. Davies EB. Tranylcypromine and cheese [letter]. Lancet 1963;2:691-692
3. Asatoor AM, Levi AJ, Milne MD. Tranylcypromine and cheese. Lancet 1963;2:733
4. Sullivan EA, Shulman KI. Diet and monoamine oxidase inhibitors: a reexamination. Can J Psychiatry 1984;29:707-711
5. Shulman KI, Walker SE, McKenzie S, et al. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol 1989;9:397-402
6. DaPrada M, Zürcher G, Wuthrich I, et al. On tyramine. food, beverages and the reversible MAO inhibitor moclobemide. J Neurol Transm 1988;26(suppl):31-56
7. Sen NP. Analysis and significance of tyramine in foods. J Food Sci 1969;34:22-26
8. McCabe BJ. Dietary tyramine and other presser amines in MAOI regimens: a review. J Am Diet Assoc 1986;86:1059-1064
9. DaPrada M, Zürcher G. Tyramine content of preserved and fermented foods or condiments of Far Eastern cuisine. Psychopharmacology (Berl) 1992;106(suppl):S32-S34
10. Folks DG. Monoamine oxidase inhibitors: a reappraisal of dietary considerations. J Clin Psychopharmacol 1983;3:249-252
11. O'Reilly RL. Are the monoamine oxidase inhibitors facing extinction? Can J Psychiatry 1991;36:186-189
12. Liebowitz MR, Hollander E, Schneier F, et al. Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders. Acta Psychiatr Scand Suppl 1990;82(suppl 360):29-34
13. Brown CS. Monoamine oxidase inhibitors: safety and efficacy issues. Drug Intell Clin Pharm 1988;22:232-235
14. Liebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988;45:128-137
15. McGrath RJ, Stewart JW, Harrison WM. et al. Predictive value of symptoms of atypical depression for differential drug treatment outcome. J Clin Psychopharmacol 1992;12:197-202
16. Vallejo J, Gastro C. Catalan R, et al. Double-blind study of imipramine versus phenelzine in melancholias and dysthymic disorders. Br J Psychiatry 1987;151:639-642
17. Himmelhoch JM, Thase ME, Mallinger AG, et al. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991;148: 910-916
18. Roose SP, Glassman AH, Walsh BT, et al. Tricyclic non-responders: phenomenology and treatment. AmJ Psychiatry 1986;143:345-348
19. Georgotas A, McCue RE, Hapworih W. Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly. Biol Psychiatry 1986;21:1155-1166
20. Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia: a placebo-controlled comparison. Arch Gen Psychiatry 1992;49:290-300
21. Versiani M. Nardi AE, Mundim FD. et al. Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine. Br J Psychiatry 1992;161:353-360
22. Angst J, Stabl M. Efficacy of moclobemide in different patient groups: a meta-analysis of studies. Psychopharmacology (Berl) 1992;106(suppl): S109-S113
23. Roth M, Guelfi JD. The efficacy of reversible monoamine oxidase inhibitors in depressive illness. Can J Psychiatry 1992;37(suppl 1):18-24
24. Heinze G, Rossel L, Gabelic I, et al. Double-blind comparison of moclobemide and tranylcypromine in depression. Pharmacopsychiatry 1993;26: 240-245
25. Blackwell B, Marley E, Price J, et al. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry 1967; 113;349-365
26. Bieck PR, Antonin K. Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects. J Clin Psychopharmacol 1988;8:237-245
27. Blackwell B, Mabbitt LA. Tyramine in cheese related to hypertensive crises after monoamine oxidase inhibition. Lancet 1965;1:938-940
28. Lovenberg W Some vaso- and psychoactive substances in food: amines, stimulants, depressants, and hallucinogens. In: Toxicants Occurring Naturally in Foods. Washington, DC: National Academy of Sciences;1973:170
29. Cooper AJ. Tyramine and irreversible monoamine oxidase inhibitors in clinical practice. Br J Psychiatry 1989:155(suppl 6):38-45
30. Boulton AA, Cookson B, Paulton R, Hypertensive crisis in a patient on MAOI antidepressants following a meal of beef liver. Can Med Assoc J 1970;102:1394-1395
31. Hedberg DL, Gordon MW, Glueck BC, Six cases of hypertensive crisis in patients on tranylcypromine after eating chicken livers. Am J Psychiatry 1966;122:933-937
32. Nuessle WF, Norman FC, Mille HE. Pickled herring and tranylcypromine reaction [letter]. JAMA 1965;192:726-727
33. Mesmer RE. Don't mix miso with MAOI. JAMA 1987;258:3515
34. Lee S, Wing YK. MAOI and monosodium glutamate interaction [letter]. J Clin Psychiatry 1991;52:43
35. Balon R, Pohl R, Yeragani VK. et al. Monosodium glutamate and tranylcypromine administration in healthy subjects. J Clin Psychiatry 1991;51: 303-306
36. Shader RI. Since my return from China, many of my colleagues have asked, "did you learn anything about MAOIs and Chinese food?" [Question the Experts] J Clin Psychopharmacol 1988;8:79
37. Hodge JV, Nye JR, Emerson GW, Monoamine oxidase inhibitors, broad beans, and hypertension [letter]. Lancet 1964;1:1108
38. Blomley DJ. Monoamine oxidase inhibitors. Lancet 1964;2:1181-1182
39. Lippman SB, Nash K. Monoamine oxidase inhibitor update: potential adverse food and drug interactions. Drug Safety 1990;5:195-204
40. Kelly D, Guirguis W, Frommer E, et al. Treatment of phobic states with antidepressants: a retrospective study of 246 patients. BrJ Psychiatry 1970;116: 387-398
41. Krikler DM, Lewis B. Dangers of natural foodstuffs [letter]. Lancet 1965; 1:1166
42. Sandier M, Youdim MBH, Hannington E. A phenylethylamine oxidizing defect in migraine. Nature 1974;250:335-337
43. Rice SL, Eitenmiller RR, Koehler PE. Biologically active amines in food: a review. Journal of Milk and Food Technology 1976;39:353-358
44. Horwitz D, Lovenberg W, Engelman K, et al. Monoamine oxidase inhibitors, tyramine and cheese. JAMA 1964;188:1108-1110
45. Littlewood JT, Glover V, Davies PTG. et al. Red wine as a cause of migraine. Lancet 1988;1:558-559
46. Hannah P, Glover V, Sandier M. Tyramine in wine and beer [letter]. Lancet 1988;1:879
47. Vidaud Z, Gonzalez E, Gancia Roche MO. Some considerations about the tyramine content of some Cuban beers and wines. Die Nahrung 1989; 33:793-794
48. Tailor SAN, Shulman KI, Walker SE, et al. Hypertensive episode associated with phenelzine and tap beer: a reanalysis of the role of pressor amines in beer. J Clin Psychopharmacol 1994;14:5-14
49. Thakore J, Dinan TG, Kelleher M. Alcohol-free beer and the irreversible monoamine oxidase inhibitors. Int Clin Psychopharmacol 1992;7: 59-60
50. Murray JA, Walker JF, Doyle JS. Tyramine in alcohol-free beer [letter]. Lancet 1988;1:1167-1168
51. Draper R, Sandier M, Walker PL. Clinical curio: monoamine oxidase inhibitors and non-alcoholic beer. BMJ 1984;289:308
52. Gelenberg AJ. Hold the suds. Biological Therapies in Psychiatry [newsletter] 1994;17:27-28
53. Neil JF, Licata SM, May SJ, et al. Dietary noncompliance during treatment with tranylcypromine. J Clin Psychiatry 1979;40:33-37